

UPPA PAU, France, Europa



Associations for the Reciprocal and Mutual Sharing of Advantages and Disadvantages: Applicative Insights in Prevention or Cure of AIDS, Cancer and Leprous Diseases.

Pierre BRICAGE

Cancer is a Breaking of the Cell's Association for the Reciprocal and Mutual Sharing of Advantages and Disadvantages Through an Aggression that Results in a Lack of Non-Autonomy.

GOOD AFTERNOON

THANK YOU FOR YOUR ATTENDANCE


PREVIOUSLY I HAVE SHOWN WHAT CANCER IS AND HOW TO TREAT IT.

NOW, I WILL TO POINT ON THE FACT THAT "CANCER, AIDS AND LEPROSY ANYHOW RESULT OF A DIS-FUNCTIONING OF AN ASSOCIATION FOR THE RECIPROCAL AND MUTUAL SHARING OF ADVANTAGES AND DISADVANTAGES (IN BRIEF ARMSADA)."


THEN, I WILL SHOW HOW THAT **PARADIGM OF ARMSADA** IS SO USEFUL TO DESIGN BOTH A CANCER CURATIVE VACCINE AND A HIV CURATIVE VACCINE.



Systemic Complexity for human development in the 21st century
Systemic Complexity : new prospects to complex system theory
7th Congress of the UES **Systems Science European Union** Lisbon, Dec. 17-19, 2008



ShareAlike



This work is licensed under the
Creative Commons
Attribution-NonCommercial-NoDerivs
License

Ce travail est protégé par une licence
Creative Commons

(559 Nathan Abbott Way, Stanford, California 94305, USA)

au profit de l' **UES**

Union Européenne de Systémique

Il peut être copié et distribué gratuitement, uniquement dans un but non-commercial,
mais sans modification, et à condition que soit indiqués

It can be copied and distributed, only in a non-commercial purpose, but without modification, and provided with the indications of

the origin/la source : <http://www.afscet.asso.fr/resSystemica/Lisboa08/bricageCuration.pdf>

the title/le titre : [Associations for the reciprocal and mutual sharing of advantages and disadvantages: applicative insights in prevention or cure of AIDS, cancer and leprous diseases. \(slides presentation\)](#)

the author/l'auteur : **BRICAGE Pierre**

the pages/la pagination : **22 p.**

the year/l'année : **2008**



& the book/la publication: [7th Systems Science European Union Congress Proceedings, Lisboa, Portugal.](#)

Attribution Non-Commerciale, Partage À l'Identique
Urhebernennung, Nicht-kommerziell, Gegenseitigkeit
Atribución No comercial, Compartir en igualdad
Atribuição Não-Comercial, Partilha em Igualdade

CANCER	AIDS	LEPROSY	ARMSADA	VACCINE
WHAT? 05	WHAT? 05	WHAT? 09	WHAT? 09	to eat 10
WHY? 11	WHY? 11	WHY? 10	WHY? 10	paradigm 18
WHEN? 07	WHEN? 07	WHEN? 07	WHEN? 07	CANC 07
HOW? 13	HOW? 13	HOW? 12	HOW? 04	buffer 07
paradigm 18	cure 16	cure 12	fitness 04	
<p>Cancer is a Strategy to Cells Resistor for the Reciprocal and Mutual Sharing of Advantages and Disadvantages Through an Aggression that Results in a Lack of Non-Autonomy</p>		<p>Associations for the Reciprocal and Mutual Sharing of Advantages and Disadvantages. Applicative Insights in Prevention or Cure of AIDS, Cancer and Leprous Diseases.</p>		
FAQ	dangers	curative	CANCER	ARMSADA
to eat 02	exogenous 06	therapy 17	introduc 01	cell 14
same r 08	endogen 06	stem c 17	conclusion 03	arms 03
	freeing 15			types 03
				conclusion 03

Associations for the Reciprocal and Mutual
 Sharing of Advantages and Disadvantages.
 Applicative Insights in Prevention or Cure
 of AIDS, Cancer and Leprous Diseases.



AIDS CANCER



AIDS LEPROSY



ARMSADA CURATIVE



ARMSADA



PREVIOUSLY I HAVE SHOWN WHAT IS AN ARMSADA AND HOW IT MERGES.
HOW & WHY AIDS AND CANCER ARE SIMILAR DIS-FUNCTIONMENTS?
HOW & WHY AIDS AND LEPROSY ARE SIMILAR AGGRESSIONS?
HOW TO CURE AIDS OR CANCER? OR ANY VIRAL DISEASE?

the **to eat** & not **"to be eaten"** arms' race

parceners

predator

prey

prey

predator

TO SURVIVE IT IS "TO EAT".

FOR EXAMPLE, AN AMOEBA IS A PREDATOR WHICH EATS MOLDS WHICH ARE PREYS. BUT THE AMOEBA ITSELF MAY ALSO BE A PREY FOR BACTERIA.

TO SURVIVE IT IS "TO EAT AND NOT TO BE EATEN"!


IN ORDER TO SURVIVE LIVING SYSTEMS BUILD ASSOCIATIONS OF PARTNERS, LIKE THE CELL, IN WHICH THE ORGANELLES, LIKE MITOCHONDRIA OR PEROXISOMES, ARE **PARCENERS**, THE WHOLE BEING AN ENDOSYNCENOSIS.

+	Parasitism	Commensalism	Mutualism
		Neutralism	Commensalism
	Competition		Parasitism
0			
-			
	-	0	+

- Mutualism – both species benefit
- Commensalism – one species benefits, the other is unaffected
- Parasitism – one species benefits, the other is harmed
- Competition – neither species benefits
- Neutralism – both species are unaffected

ARMSADA – only benefits (=advantages) for the Whole but - there are no advantages without disadvantages
 Association for the **RECIPROCAL** (both Predator/Prey) and **MUTUAL** (Mutualism)

SHARING of Advantages & DisAdvantages





USUALLY **THE RELATIONSHIP BETWEEN ORGANISMS** ARE DESCRIBED AS PARASITISM, COMMENSALISM, MUTUALISM, COMPETITION OR NEUTRALISM.

IN THE CASE OF A PREDATOR/PREY FIGHT, 2 SITUATIONS ARE EVIDENCED: THE PREDATOR WINS AND EATS THE PREY OR THE PREDATOR LOSES AND THE PREY WINS. BUT THERE ARE 2 MORE SITUATIONS: THE TWO LOSE TOGETHER OR THE TWO WIN TOGETHER. ARMSADA IS THE RESULT OF THE FACT THAT THE TWO SIMULTANEOUSLY WIN AND LOSE, MERGING INTO A NEW WHOLE.

HOW DOES THAT HAPPEN?


AN ALIVE SYSTEM MAY BE DESCRIBED WITH ITS **ENDOPHYSIOTOPE** (**ENDO: INTERNAL, TOPE: SPACE, PHYSIO: OF FUNCTIONING**) WHICH IS INTEGRATED INTO AN **ECOEXOTOPE** OF SURVIVAL (**EXO: EXTERNAL, TOPE: SPACE, OF ECO: INHABITATION**), EVERY LIVING SYSTEM IS SIMULTANEOUSLY A GUEST OF AN ECOEXOTOPE OF **HOSTING** AND MAY BE THE **HOST** OF OTHER ENDOPHYSIOTOPES FOR WHICH ITS ENDOPHYSIOTOPE IS AN ECOEXOTOPE.





LET'S PICTURE THE FATES OF ORGANISMS' FIGHTS WITH THE SIMPLEX GRAPHIC REPRESENTATION:

- THE PREY WINS, OR - THE PREDATOR WINS,
- THE TWO TOGETHER LOSE,
- THE TWO TOGETHER WIN AND LOSE SIMULTANEOUSLY AND A NEW WHOLE IS MERGING.



Gregson, S. et al . Sexual mixing patterns and sex-differentials in teenage exposure to HIV infection in rural Zimbabwe. *The Lancet* 359, 1896 - 1903 (2002). [\[Article\]](#)

Glynn, J. R. et al . Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia. *AIDS* 15, (Suppl 4) S51 - S60 (2001). [\[Article\]](#)

HIV life cycle



ecoexotope


prey



predator



budding



AIDS IS THE RESULT OF **A PREDATOR/PREY RELATIONSHIP** IN WHICH THE PREYS ARE OUR CELLS AND THE PREDATOR IS THE HIV.

THE WHOLE LIFE CYCLE OF THE VIRUS IS PERFECTLY KNOWN AND WE HAVE DRUGS FOR STOPPING OR DAMAGING EACH OF THE 10 STEPS OF ITS CYCLE. BUT WE CAN USE ONLY 3 DRUGS SIMULTANEOUSLY BECAUSE THE DRUGS MORE EASILY KILL THE SICK INDIVIDUAL THAN THE VIRUS!

into humans, perhaps when they ate infected meat. One strain, called HIV-1, then spread all over the world.



Papillomavirus



THE HIV LIKE OTHER VIRUSES IS **CARCINOGENIC** AND LINKED TO MULTIPLE SCLEROSIS BECAUSE IT ALLOWS THE **EVASION OF OTHER ENDOGENOUS CONSTRAINED VIRUSES WHICH ARE HOSTED BY THE HUMAN GENOME.**



HOW ARE THESE ENDOGENOUS VIRUSES FREED?



uncontrolled not-constrained dangers **human exogenous viruses**

cell level **organism level** **virus**



Upstream Regulatory Element



TYPE C-LIKE HUMAN RETROVIRUS LINKED TO MULTIPLE SCLEROSIS (WO/1993/007259)



ENDOGENETIC RETROVIRAL SEQUENCES, ASSOCIATED WITH AUTOIMMUNE DISEASES OR WITH PREGNANCY DISORDERS

free articles online



The costs for each type of genes' regulation: the regulation load.
The robustness of the control elements of genes' governance.

How is an ARMSADA "buffered" ?



types of control	gene sequences	protein synthesis	lag duration
never expressed	1	0	infinite

THERE ARE 4 TYPES OF GENES EXPRESSION:


- GENES THAT ARE **EXPRESSED ONLY AFTER ACTIVATION**,
- GENES THAT ARE **EXPRESSED ONLY AFTER AN INHIBITION BREAKAGE**,
- GENES THAT ARE **EVER EXPRESSED**, FREED, CONSTITUTIVE, AND
- GENES THAT ARE **NEVER EXPRESSED** (LOCKED, DORMANT).

IN FACT, GENES GOVERNANCE IS A MIXING OF ALL OF THAT 4 REGULATION TYPES, WHICH ALLOWS **FEED-BACK MECHANISMS**.

IN TERM OF **COSTS**, INHIBITION BREAKAGE IS THE MOST POWERFUL TYPE OF CONSTRAINING AND THE CHEAPER.

EVEN THE HTLV1 AUTOCONTROLS ITSELF IN THAT WAY.

AN EXAMPLE OF EVASION IS THE LOST OF AN INHIBITION WHICH FREES PREVIOUSLY LOCKED DANGERS OR REPRESSED ONES.






to survive it is:
"to eat" and not "to be eaten"


TO SURVIVE IT IS "TO EAT AND NOT TO BE EATEN".

THE RELATIONSHIP BETWEEN HIV AND CELLS ARE THE SAME THAT THE ONES BETWEEN A PREDATOR AND ITS PREYS. HIV POPULATIONS EVOLVE AS DO OTHER BLOOD CELLS PREDATORS (LIKE IN TRYPANOSOMES DISEASES), WITH THE 4 FATES:

- THE PREY WINS, - THE PREDATOR WINS, - THE 2 LOSE, - NO ONE WINS OR LOSES AND THE 2 TOGETHER WIN AND LOSE.

A STEADY-STATE MUST INSTALL BETWEEN THE PREDATOR AND ITS PREY, LIKE IT HAPPENS BETWEEN A BACTERIOPHAGE AND ITS BACTERIAL HOST, FOR THE MERGING OF AN ARMSADA, WHICH IS A NEW BLUEPRINT.





IN SOME ASPECTS AIDS AND CANCER ARE SIMILAR: THE VIRUS/HOST FIGHT IS AN ARMS RACE.

IN THE CASE OF BACTERIOPHAGES, USUALLY VIRUSES OF THE ECOEXOTOPE KILL THE BACTERIAL HOST: PROBABILITY 1.

RARELY (PROBABILITY $10^{\text{exponent}-3}$), THE PHAGE DOES NOT KILL ITS HOST AND THE 2 SURVIVE TOGETHER. BUT THEIR ASSOCIATION MAY BE DISRUPT BY THERMAL, RADIATIVE OR CHEMICAL STRESSES, LIKE IN CANCER.

"THE SAME" WHEN AN EXOGENOUS VIRUS ENTERS A CELL, OR WHEN AN ENDOGENOUS ONE EVADES INTO THE CELL. THE CELL USUALLY IS KILLED: PROBABILITY 1. BUT, VERY RARELY, PROBABILITY $10^{\text{exponent}-6}$, IT SURVIVES AND NO VIRUS IS PRODUCED, BECAUSE, THE 2, THE CELL AND THE VIRUS, SURVIVE TOGETHER GIVING RISE TO A CANCER CELL.

EXCEPTIONNALLY, THE VIRUS AND THE CELL GIVE RISE TO A NEW WHOLE, AN ARMSADA IN WHICH THE VIRUS IS DEFINITELY INTEGRATED INTO THE CELL'S ENDOPHYSIOTOPE: PROBABILITY SUPPOSED TO BE $10^{\text{exponent}-12}$. NO VIRUS IS PRODUCED, NO MORE CANCER CELL.

THAT IS THE PARADIGM OF ARMSADA MERGING, EVEN IF THIS EVENT IS AN EXCEPTION, SOON OR LATE IT BURSTS.

partition
biotope

partition





Fig. 1.- 1. The lepromatous form of the disease, at the organism's level



2. The tuberculoid form of the disease.



Fig. 3.- Observation au microscope optique. A l'invasion
x 1000 (Fisch Nielsen)

Fig. 4.- Lymphocyte hypertrophie
x 1200

4. A hosting cell.
non-invited guest



Fig. 5.- Sequestration lymphocytaire du microbe

Mycobacterium leprae within the human cells:
The predator/prey association



**guest/host
arms race
escalation**



5. The sequestration of the invading danger & the predator/prey relationship.


DO COMPARE NOW AIDS AND LEPROSY. THERE ARE 2 FORMS OF THE LEPROUS DISEASE: **THE LEPROMATOUS** ONE, WITH ULCERATIONS, AND THE **TUBERCULOID** ONE, WITH MUTILATIONS. **WHY SUCH A DIFFERENCE?**

AS PREVIOUSLY SHOWN IT IS THE RESULT OF **A GUEST/HOST ARMS RACE ESCALATION.**

LIKE THE VIRUS IN AIDS, THE BACILLI ARE SEQUESTERED INTO THE LYMPHOCYTES WHERE THEY ARE "NON-INVITED GUESTS".

HOW DO THAT KIND OF PREDATOR/PREY RELATIONSHIP MAY EVOLVE?

FIGURE 3: "Like with viruses"...
a dynamic war is running in between the bacterial and cell compartments.



Nikolayevskyy V.V. (2007) Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in *Mycobacterium tuberculosis* strains from the southern Ukraine. *Clinical Microbiology and Infection* 13(2): 129-138.

In the states of the former Soviet Union, the last 15 years have been characterised by a dramatic rise in the incidence of TB associated mortality with a converging human immunodeficiency virus (HIV)/AIDS epidemic.

Suzuki K. & al. (2006) High-level expression of pseudogenes in *Mycobacterium leprae*. *FEMS Microbiology Letters* 259(2): 208-214.

Ro Y.T. & al. (2003) Purification, characterization, and physiological response of a catalase-peroxidase in *Mycobacterium* sp. strain JC1 DSM 3803 grown on methanol. *FEMS Microbiology Letters* 226(2): 397-403.


Bricage P. (1979) Recherche d'activateurs de croissance pour une culture in vitro de Mycobactéries d'origine lépreuse. I. Les alcools, métabolites ou facteurs de croissance. *Ann. Ctr Rech. Biol. sur la Lèpre, Dakar*, 1: 5-12.

Grant I.R. & al. (2001) *Mycobacterium avium* ssp. *paratuberculosis*: its incidence, heat resistance and detection in milk and dairy products.

IN THE LEPROUS DISEASE, LIKE WITH VIRUSES, A DYNAMIC WAR IS RUNNING BETWEEN THE BACTERIAL AND CELLULAR COMPARTMENTS.

THE TUBERCULOID FORM \bar{I} IS THE RESULT OF THE DEFEAT OF THE 2 FIGHTERS, EACH ONE DESTROYING THE OTHER ONE. THE LEPROMATOUS FORM \bar{II} IS THE RESULT OF THE VICTORY OF THE PREDATOR BACILLI.

A NO-WINNER AND NO-LOSER STEADY-STATE IS PREDICTIBLE LIKE THE ONE THAT REALLY MERGED WHEN THE MITOCHONDRION DID INTEGRATE THE EUKARYOTIC CELL.




Long, E. M., Martin, H. L., Kreiss, J. K., Rainwater, S. M. J., Lavreys, L., Jackson, D. J., Rakwar, J., Mandaliya, K. & Overbaugh, J. Gender differences in HIV-1 diversity at time of infection *Nature Medicine* **6**, 71 - 75 (2000).

Sexual transmission of HIV from man to woman results in

predator

ACTUALLY THAT "NO-WINNER AND NO-LOSER" STATE MUST EXIST IN ALL SITUATIONS OF CONFLICT.


IN AIDS WHY SOME AT HIGH RISKS ARE STILL FREE OF VIRUSES?



transmission from woman to man,

exogenous ecoexotope dangers

The HIV virus changes its outer protein coat (shown in orange above) to evade the immune system.





Derdeyn, C. A. et al. *Science*, **303**, 2019 - 2022, (2004). **[Homepage]**

to survive it is:

"to eat" and not "to be eaten"

Why some at high risk are still HIV-free

FIGURE 4: The structural & functional ergodicity of the living systems runs through the juxtaposition & encasement of previous living organisations.



To survive it is
"to eat & not to be eaten".

Autophagy is Essential for
Preimplantation Development of Mouse Embryos.
Tsukamoto S. & al. (2008) Science 5885: 117-120.

1a: for every living system, to survive it is
"to eat" & "not to be eaten".
1b: but, it is impossible "not to be eaten"...
everyone, soon or late, is eaten!

4: The increase of the "hosting" capacity of an
ecoexotope is always merging from an increase
in the capacity of "to be hosted" of the
endophysiotope.

5a: The ecoexotope of integration temporarily
"updates" long-lasting choices of organization.


An environmental heritage (the EcoEcto) allows "to
eat". But it can not allow "not to be eaten". It is transformed
along the way life goes through. There are different versions of
that heritage and all have ~~some common and different~~

3a: Every living system can not be "extracted"

DURING THE FIRST STEPS OF THE LIFE ON EARTH THERE WERE ONLY BACTERIA THAT SHARED A COMMON ECOEXOTOPE. BUT SUDDENLY A NEW BLUEPRINT MERGED: THE CELL. WHY?

THIS WAS THE RESULT OF JUXTAPOSITIONS AND ENCASEMENTS OF PREVIOUSLY FREE ANTAGONISTIC MONERA, TO MAKE A NEW WHOLE. SURELY, THE PROCESS WAS TRIGGERED BY A RNA VIRUS, WHICH IS STILL PRESENT IN OUR CELLS AS THE CENTROSOME,

"A RELIC OF A VIRUS" WHICH IS STILL DIVIDING WHEN A CELL DIVIDES.




Mitochondria as Drivers of Metastasis

Ishikawa K. & al. (2008) Science 5876: 661-664. ROS-
Generating Mitochondrial DNA Mutations Can Regulate
Tumor Cell Metastasis.

We used cytoplasmic hybrid technology to replace the endogenous mitochondrial DNA in a mouse tumor cell line that was poorly metastatic with mitochondrial DNA from a cell line that was highly metastatic, and vice versa.

The recipient tumor cells acquired the metastatic potential of the transferred mitochondrial DNA.

In one tumor cell line, the mitochondrial DNA conferring high metastatic potential was found to harbor mutations that led to up-regulation of nuclear genes involved in metastasis.



The carboxysome functions as a simple organelle by sequestering enzymes involved in carbon fixation.

The carboxysome is a bacterial

OTHER VIRAL-LIKE CONSTRAINED DANGERS ARE STILL PRESENT IN CELLS, LIKE THE PROTEIN CRISTALS THAT BURST IN MITOCHONDRIA OR IN PEROXISOMES AT CERTAIN STEPS OF DEVELOPMENT.

pentameric building blocks such as those found in certain viral capsids.

4 abundant shell proteins from 2 known types of carboxysomes are known to form hexamers.

Tanaka S. & al. (2008) Atomic-Level Models of the Bacterial Carboxysome Shell. Science 319(5866): 1083-1086.




TABLE 7: The ex-vivo curative vaccine technology.

A therapy of the HIV with the HIV.

A "technologically created natural" phenotype of resistance to the AIDS virus.

The paradigm:

The constrained hosted dangers are advantages.

The dangers, if de-constrained or lost, become disadvantages.

The technology: <http://www.armsada.com/2116746/MSM>

THE EX-VIVO **HIV CURATIVE VACCINE TECHNOLOGY** I PROPOSED IN SEPTEMBER 2005 IS **THE APPLICATION OF THAT ARMSADA PARADIGM.**

THE PARADIGM: THE CONSTRAINED DANGERS ARE ADVANTAGES;

THE PROCEDURE: AFTER IN VIVO TAKING UP OF STEM CELLS INTO A SICK PATIENT AND THEIR IN VITRO CULTURE, THEIR PROGENY IS CONFRONTED WITH HIV TO ALLOW THE SELECTION OF CELLS THAT ARE STILL ALIVE, VIRUS FREE AND RESISTANT TO HIV KILLING, BECAUSE OF THEIR METAMORPHOSIS THROUGH HIV INTEGRATION.

AFTER THE TEST OF THEIR NON-CANCEROUS STATE, ENGRAFTED INTO THE DONOR THEY WILL CURE THE DISEASE.

The principle is the same as that of the vaccination against the rabies.

- Only the contaminated individual is treated.

- Drugs are used only as *in vivo* "retardants",

giving the delay for taking *in vitro* an advance on the virus.

- The clone is grafted to the same individual with no risk of rejection.

- It is a gene therapy of AIDS with HIV (not with an other viral vector).

That allows to by-pass the epidemiological differences which are due to the sex phenotypes and to avoid the risks of intergeneration genetic restoration (cytoplasmic heredity).

We can hope a **clonal advantage** in favour of the transformed cells
"The virus can even pass several times."

Inconveniences and risks ?

- the technology is **expensive** but less than the usual multi-annual treatments, with very heavy undesired effects, and which succeed only to delay the death of the individual, and to select drug-resistant viral variants, maybe more virulent ones!

- **The risk of mutation is lowered** if the virus is integrated into an **ARMSADA**. Because the mutation rate of the "naturally integrated non-expressed" DNA is several orders of magnitude lower than that of RNA or DNA free templates.

Web

Is there another approach than that of a preventative vaccine?
That of a CURATIVE one... Please do Look at :
The Metamorphoses of the Living Systems
<http://hal.archives-ouvertes.fr/hal-00130685>

Résultats 1 - 4 sur 4 pour SIDA HIV AIDS "curative vaccine".

Mise au point d'un vaccin curatif anti-SIDA
Bricage P. (2005)

HAL : hal-00130685, version 1

© CCSD Centre pour la communication scientifique directe - <http://ccsd.cnrs.fr>

Fiche détaillée

(2005)

The Metamorphoses of the Living Systems: The Associations for the Reciprocal and Mutual Sharing of Advantages and of Disadvantages.

Pierre Bricage ()¹

(19/09/2005)

The emergence of a new org merges through the simultan through the maintenance of the ecocotope of its survival partner owns its place, thro advantages and of deadw

LESS THAN 3 YEARS LATER, GERMAN SCIENTISTS HAVE ACHIEVED THE FIRST STEP OF THAT HIV CURATIVE VACCINE WAY WITH ADULT STEM CELL TRANSPLANT AIDS CURATION.

AND NOWADAYS WE CAN EASILY OBTAIN A LOT OF BLOOD STEM CELLS.

endophysiologies of the ecocotopes are changing, it is the way to make a new networking mode of integration. The association merges through the interactive fitness between the "welcome" capacity of the ecocotope and the "to be welcomed" capacity of the endophysiologie of each partner. This is allowed through the simultaneous losses by all partners of the capacity to kill the other ones. <http://minilien.com/?R9E2rFXJlc> 5. <http://www.minilien.com/?LUeZdsNCH>

sum of its parts. If partner is allowed d of the whole into are allowed. Each mutual sharing of the whole, if the

¹ : Systems Evolution Workshop (SEW)
AFSCET

<http://minilien.com/?R9E2rFXJlc>



Stem Cells on Demand

Infection of adult mouse cells with viruses expressing genes of transcription factors generates pluripotent stem cells that resemble embryonic stem cells.

Viruses commonly used for this procedure permanently alter the cells' genome and can cause tumors in animals, and thus these cells cannot be used directly for cell therapy.

Stadtfeld M. & al. (2008) Induced Pluripotent Stem Cells Generated Without Viral Integration. *Science* 322(5903): 945-949.

produced mouse iPS cells by transiently exposing adult skin and liver cells to these transcription factor genes using adenoviruses (that generally do not integrate into the genome).

Friday, November 14, 2008

Adult stem cell transplant cures AIDS

New York Times

Doctors in Berlin are reporting that they cured a man of AIDS by giving him transplanted blood stem cells from a person naturally resistant to the virus.



Scientists Create Blood From Stem Cells



August 19, 2008 | 11:36:04 AM

More Stem Cells on Demand

Okita K. & al. (2008) Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors. *Science* 322(5903): 949-953.

Induced pluripotent stem (iPS) cells have been generated from human somatic cells by using retroviruses or lentiviruses. To rule out any risk of viral vectors integrating into the host genome and causing tumors, do use a plasmid transfection procedure to introduce transcription factor genes into embryonic fibroblasts to make pluripotent cells. there was no evidence of plasmid integration and, although less efficient than other methods, this method looks like it will offer a safer way of inducing pluripotent stem cells.

Cancer curative vaccine: the paradigm & the procedure.



AS I PRESENTED IT TO YOU PREVIOUSLY, THAT SAME PARADIGM ALLOWS THE DESIGN OF **A CANCER CURATIVE VACCINE PROCEDURE WHICH IS SIMILAR,** USING SIMULTANEOUSLY THE **INVASION OF EXOGENOUS VIRUSES** AND THE INDUCED **EVASION OF ENDOGENOUS ONES.**
I DO HOPE THAT ONLY 3 YEARS WILL BE SUFFICIENT TO DO THE SAME SUCCESS IN CANCER CURATION THAN IN HIV CURATION.

ALL THE DATA RELATED TO THE PREVIOUS PROTOCOL OF THE HIV CURATIVE VACCINE AND TO THIS NEW CANCER CURATIVE VACCINE ARE AVAILABLE **FREE (CREATIVE COMMON LICENCE) ON THE NET** AT THE FOLLOWING ADRESSES...

ARMSADA

UESlisboaPBsymbiosisRef.pdf

<http://minilien.com/?gEHtVdd60o>

HIV induced AIDS CURATIVE VACCINE

sept. 2005 PARIS

UESlisboaPBaidsRef.pdf

<http://minilien.com/?USaw1HHJ4Z>

CANCER CURATIVE VACCINE

dec. 2008 LISBOA

UESlisboaPBcancerRef.pdf

<http://www.minilien.com/?oUtHBBpz46>

LEPROSY



UESlisboaPBlepraeRef.pdf

<http://minilien.com/?iUZluv4lpL>

CANCER	AIDS	LEPROSY	ARMSADA	VACCINE
WHAT? 05	WHAT? 05	WHAT? 09	WHAT? 07	to eat 18
WHY? 11	WHY? 11	WHY? 10	WHY? 07	paradigm 18
WHEN? 13	WHEN? 13	WHEN? 10	WHEN? 07	CANCER 07
HOW? 13	HOW? 13	HOW? 10	HOW? 04	buffer 07
paradigm 13	curable 13	curable 12	fitness 04	
<p>Cancer is a Breakdown of the Cells Association for the Reciprocal and Mutual Sharing of Advantages and Disadvantages Through an Aggressive and Results in a Lack of Vi-Accounts</p>		<p>Associations for the Reciprocal and Mutual Sharing of Advantages and Disadvantages: Applicative Insights in Prevention or Cure of AIDS, Cancer and Leprous Diseases.</p>		
FAQ	dangers	curative	CANCER	ARMSADA
to eat 02	exogenous 06	therapy 17	introduction 01	cell 14
arms r 08	endogen 06	stem c 17	conclusion 01	attack 03
	freeing 15			types 14
	Integr 15			conclusion 14



THANK YOU FOR YOUR LISTENING.
I AM NOW WAITING FOR YOUR QUESTIONS ABOUT CANCER, HIV, LEPROSY OR ARMSADA OR THE CURATIVE VACCINE PROCEDURES.



Associations for the Reciprocal and Mutual Sharing of Advantages and Disadvantages: Applicative Insights in Prevention or Cure of AIDS, Cancer and Leprous Diseases.



ALL THE DATA RELATED TO THE PREVIOUS PROTOCOL OF THE HIV CURATIVE VACCINE AND TO THIS NEW CANCER CURATIVE VACCINE ARE AVAILABLE FREE (CREATIVE COMMON LICENCE) ON THE NET AT THE FOLLOWING ADDRESSES:

ARMSADA Oct. 2002, HERAKLION (file: [UESlisboaPBsymbiosisRef.pdf](#))
<http://minilien.com/?gEHtVdd60q>

AIDS CURATIVE VACCINE Sept. 2005, PARIS (file: [UESlisboaPBaidsRef.pdf](#))
<http://minilien.com/?USaw1HHJ4Z>

CANCER CURATIVE VACCINE Dec. 2008, LISBOA (file: [UESlisboaPBcancerRef.pdf](#))
<http://www.minilien.com/?oUtHBBpz46>

